MD Clinic Praga
Welcome,         Profile    Billing    Logout  
 3 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MARQUES, Ana-Raquel
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
drapier, sophie
LIGHTHOUSE, NCT05418673: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
EARLY-PUMP, NCT02864004: Apomorphine Pump in Early Stage of Parkinson's Disease

Active, not recruiting
3
134
Europe
Apomorphine, Apokinon, Best Medical Treatment
Rennes University Hospital
Parkinson's Disease
12/23
01/25
PIMPARK, NCT03947216: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Recruiting
2
130
Europe
Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound, Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Blood analysis, Cardiac monitoring
University Hospital, Strasbourg, France, NS-PARK, EUCLID Clinical Trial Platform, F-CRIN
Parkinson Disease
10/24
12/24
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
PERSO-PERF, NCT06080399: Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

Recruiting
N/A
70
Europe
Continuous subcutaneous apomorphine infusion (CSAI)
University Hospital, Toulouse, ELIVIE France, EVER Pharma France SAS, NHC SAS, France, Orkyn', ETPARK Association, Toulouse, France
Parkinson Disease
04/26
04/26
Koziorowski, Dariusz
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Active, not recruiting
2
506
Europe, US, RoW
K0706, placebo
Sun Pharma Advanced Research Company Limited
Early Parkinson Disease
03/24
03/24
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Recruiting
2
735
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
11/27
02/30
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting
N/A
150
Europe, US
This is an observational study.
Asklepios Biopharmaceutical, Inc.
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
08/25
10/25

Download Options